Cancer Sci:雄激素抵抗性前列腺癌中细胞分裂相关1(CDCA1)肽接种疫苗**阶段临床试验

2017-05-21 AlexYang MedSci原创

最近,研究人员筛选了细胞分裂相关1(CDCA1),并且作为致癌基因在几种癌症,包括前列腺癌中超表达。研究人员同样鉴定了一个高度免疫的HLA-A*2402限制性表位多肽,并且与CDCA1蛋白的部分一致。另外,利用CDCA1肽接种疫苗,对患有雄激素抵抗性前列腺癌(CRPC)的病人进行了第一阶段的临床试验。研究包括了多烯紫杉醇化疗失败的具有HLA-A*2402的12名CRPC病人,并让他们接受带有Mon

最近,研究人员筛选了细胞分裂相关1(CDCA1),并且作为致癌基因在几种癌症,包括前列腺癌中超表达。研究人员同样鉴定了一个高度免疫的HLA-A*2402限制性表位多肽,并且与CDCA1蛋白的部分一致。另外,利用CDCA1肽接种疫苗,对患有雄激素抵抗性前列腺癌(CRPC)的病人进行了第一阶段的临床试验。

研究包括了多烯紫杉醇化疗失败的具有HLA-A*2402的12名CRPC病人,并让他们接受带有Montani -de ISA51VG佐剂的乳液状的CDCA1肽皮下注射,注射频率为一周一次并且为剂量增加的方式(1.0或者3.0毫克/每人,6名病人接受每种剂量)。

研究发现,最初的端点是安全的,并且第二个端点具有免疫学和临床响应。CDCA1肽接种疫苗耐受性很好,没有任何严重的负作用。另外,研究人员利用酶联免疫实验和dextramer实验在3名接受1.0毫克剂量的病人中和5名接受3.0毫克剂量的病人中观察到了肽特异性细胞毒性T淋巴细胞(CTL)响应。总的中值生存时间为11个月,并且对CDCA1肽特异性的CTL响应在长期存活的病人中存在。最后,研究人员指出,CDCA1来源的肽疫苗治疗具有耐受性特点也许可以在CRPC病人中高效的诱导肽特异性CTLs。并且,这个新的肽疫苗疗法看起来很有发展前景。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1665929, encodeId=5d8a166592900, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Aug 11 10:26:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632342, encodeId=1cbd1632342a9, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Fri Oct 06 16:26:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205578, encodeId=ddb72055e8b9, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 02 09:48:23 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557172, encodeId=a26c155e1722a, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Tue May 23 12:26:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201306, encodeId=dc75201306fe, content=学习了,新知识,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon May 22 19:30:49 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
    2017-08-11 yige2012
  2. [GetPortalCommentsPageByObjectIdResponse(id=1665929, encodeId=5d8a166592900, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Aug 11 10:26:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632342, encodeId=1cbd1632342a9, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Fri Oct 06 16:26:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205578, encodeId=ddb72055e8b9, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 02 09:48:23 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557172, encodeId=a26c155e1722a, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Tue May 23 12:26:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201306, encodeId=dc75201306fe, content=学习了,新知识,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon May 22 19:30:49 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1665929, encodeId=5d8a166592900, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Aug 11 10:26:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632342, encodeId=1cbd1632342a9, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Fri Oct 06 16:26:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205578, encodeId=ddb72055e8b9, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 02 09:48:23 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557172, encodeId=a26c155e1722a, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Tue May 23 12:26:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201306, encodeId=dc75201306fe, content=学习了,新知识,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon May 22 19:30:49 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
    2017-06-02 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1665929, encodeId=5d8a166592900, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Aug 11 10:26:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632342, encodeId=1cbd1632342a9, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Fri Oct 06 16:26:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205578, encodeId=ddb72055e8b9, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 02 09:48:23 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557172, encodeId=a26c155e1722a, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Tue May 23 12:26:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201306, encodeId=dc75201306fe, content=学习了,新知识,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon May 22 19:30:49 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1665929, encodeId=5d8a166592900, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Aug 11 10:26:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632342, encodeId=1cbd1632342a9, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Fri Oct 06 16:26:00 CST 2017, time=2017-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205578, encodeId=ddb72055e8b9, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Jun 02 09:48:23 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557172, encodeId=a26c155e1722a, content=<a href='/topic/show?id=f611e7814e8' target=_blank style='color:#2F92EE;'>#细胞分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77814, encryptionId=f611e7814e8, topicName=细胞分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126314868296, createdName=wshxjq, createdTime=Tue May 23 12:26:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201306, encodeId=dc75201306fe, content=学习了,新知识,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Mon May 22 19:30:49 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
    2017-05-22 一个字-牛

    学习了,新知识,谢谢分享

    0

相关资讯

Cancer Res:在前列腺癌中,新的雄激素受体辅助调节因子GRHL2发挥了致瘤作用和抗转移作用

前列腺癌中,雄激素受体(AR)辅助调节因子的表达和活性的改变是驱动疾病发展和治疗出现抗性的一种重要机制。最近,研究人员利用一种新的蛋白组学技术,鉴定了一个新的AR辅助调节因子-转录因子Grainhead-like 2(GRHL2),并描述了它潜在的在AR信号通路中致瘤角色。研究发现,GRHL2与AR在前列腺肿瘤中共定位,并且在前列腺爱重频繁的扩增和上调。重要的是,GRHL2在多种前列腺癌模型系统中

Sci Rep:前列腺癌病人中,组合雄激素阻断兴奋剂引起的骨矿丢失与GnRH的比较

最近,研究人员进行了一项多中心的、预期性的和观察的研究,该研究设计用来检测持续的组合雄激素阻断(CAB)相对与GnRH兴奋剂单一治疗的疗效,主要依据是亚洲前列腺癌病人雄激素阻断治疗(ADT)12月后的骨矿密度变化情况(BMD)。研究利用了多元回归分析和用断裂风险评估工具评估的病人10年大骨折的可能性来揭示影响BMD的因素。并利用成对t检验来评估BMD从基线时间到12个月之间的变化,还对两个组进行了

Oncol Rep:钙蛋白酶和AR-V7是两个潜在的在去雄抵抗性前列腺癌细胞中,克服获得性多烯紫杉醇抗性治疗靶点

基于多烯紫杉醇的化学疗法已经广泛的应用于去雄抵抗性前列腺癌(CRPC)病人的首选疗法。然而,多烯紫杉醇的抗性机制仍然不清楚。最近,有研究人员建立了2个CRPC细胞亚系的多烯紫杉醇抗性的体内模型,并率先报道了钙蛋白酶也许在前列腺癌多烯紫杉醇抗性中具有促进作用。同时,研究人员利用钙蛋白酶抑制剂组合多烯紫杉醇改善了多烯紫杉醇抗性细胞亚系中的多烯紫杉醇的效用。更多的是,研究人员还发现了雄激素非依赖的组成性

Oncotarget: 前列腺健康指数PHI预测根治性前列腺切除术后肿瘤治疗效果和生化复发率

最近,研究人员调查了利用前列腺癌健康指数(PHI)来进行根治性前列腺切除术后病理疗效,以及生化复发率预测,并与建立的相关参数(格林森得分、病理肿瘤阶段、切除状态(Ro/1)和前列腺特异抗原)比较。在2001年到2014年年间,研究包括了460个具有术前PHI测量的案例,总共有437名病人具有完整的跟踪数据。研究结果发现,在这些437名病人中,87(19.9%)的病人发生了生化复发。研究人员利用卡方

Oncotarget: 脂肪代谢抑制可以使前列腺癌细胞对抗雄激素阻断敏感

前列腺癌(PCa)是西方男性最常见的恶性疾病并且是癌症相关死亡的第二主要原因。对于那些患有转移性激素抵抗性PCa(mCRPC)的病人,存活率是很低的,这也使得对mCRPC新的治疗方法的鉴定变得非常重要。最近,有研究人员发现,通过肉毒碱棕榈酰转移酶诱导的脂肪氧化(CPT1)缺陷可以引起生长和侵入性减弱,强化了脂肪氧化在PCa生长燃料的角色。研究人员利用免疫组化技术发现,与良性组织比较,CPT1A同工

Sci Rep: 腰臀比(WHR)是一个比身体质量指数(BMI)更好的预测因子

最近,有研究人员研究调查了在中国男性中,腰臀比(WHR)是否是一个比身体质量指数(BMI)更好的前列腺癌(PCa)预测因子。研究人员在2013年和2015年,检查了1018名经历前列腺活组织检查并且PSA≤20ng/ml的病人的数据资料,并搜集了临床数据和活检结果。研究利用逻辑回归来评估BMI、WHR和PCa发生率之间的关系,并利用ROC (AUC)下面的区域来评估不同预后模型的准确性。研究总共包